Colorectal Carcinoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Liver Neoplasms, Experimental
|
0.200 |
Biomarker
|
phenotype |
RGD |
Methyl deficiency, alterations in global histone modifications, and carcinogenesis.
|
17182829 |
2007 |
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.
|
31374203 |
2019 |
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.
|
31374203 |
2019 |
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The recognition of HAT1 in regulating tumor cell proliferation and cancer immunity indicated that HAT1 might be employed as a new diagnostic and prognostic marker and a predictive marker for pancreatic cancer therapy, especially in immune checkpoint blockade therapy.
|
30709380 |
2019 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Moreover, the in vivo experiment revealed that miR-377 overexpression or HAT1 silencing inhibited tumor growth and reduced tumor size in nude mice.
|
31152456 |
2019 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Furthermore, we found that HAT1 expression was directly correlated with the poor tumor differentiation of EC tissue, which suggested that HAT1 played an important role in esophageal carcinoma and that it could be a novel EC therapeutic target.
|
25120766 |
2014 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The recognition of HAT1 in regulating tumor cell proliferation and cancer immunity indicated that HAT1 might be employed as a new diagnostic and prognostic marker and a predictive marker for pancreatic cancer therapy, especially in immune checkpoint blockade therapy.
|
30709380 |
2019 |
Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The purpose of our investigation was to evaluate the functional relevance of miR-377 in OS and to investigate whether the mechanism was related to the histone acetyltransferase 1 (HAT1)-mediated Wnt signaling pathway.
|
31152456 |
2019 |
Osteosarcoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Ras-ERK1/2 signalling promotes the development of osteosarcoma through regulation of H4K12ac through HAT1.
|
30942624 |
2019 |
Osteosarcoma of bone
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Ras-ERK1/2 signalling promotes the development of osteosarcoma through regulation of H4K12ac through HAT1.
|
30942624 |
2019 |
Osteosarcoma of bone
|
0.020 |
Biomarker
|
disease |
BEFREE |
The purpose of our investigation was to evaluate the functional relevance of miR-377 in OS and to investigate whether the mechanism was related to the histone acetyltransferase 1 (HAT1)-mediated Wnt signaling pathway.
|
31152456 |
2019 |
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
The recognition of HAT1 in regulating tumor cell proliferation and cancer immunity indicated that HAT1 might be employed as a new diagnostic and prognostic marker and a predictive marker for pancreatic cancer therapy, especially in immune checkpoint blockade therapy.
|
30709380 |
2019 |
Childhood Osteosarcoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Ras-ERK1/2 signalling promotes the development of osteosarcoma through regulation of H4K12ac through HAT1.
|
30942624 |
2019 |
Childhood Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The purpose of our investigation was to evaluate the functional relevance of miR-377 in OS and to investigate whether the mechanism was related to the histone acetyltransferase 1 (HAT1)-mediated Wnt signaling pathway.
|
31152456 |
2019 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
RIP1-HAT1-SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer.
|
29535128 |
2018 |
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
RIP1-HAT1-SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer.
|
29535128 |
2018 |
Psoriasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that HAT1 reduces psoriasis disease activity in a clinically relevant manner.
|
31419323 |
2020 |
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the expression pattern of key histone acetyltransferase subtypes (p300, HAT1) in human atherosclerosis and to determine their role in mediating the upregulation of Nox5 in macrophages under inflammatory conditions.
|
31565149 |
2019 |
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the expression pattern of key histone acetyltransferase subtypes (p300, HAT1) in human atherosclerosis and to determine their role in mediating the upregulation of Nox5 in macrophages under inflammatory conditions.
|
31565149 |
2019 |
Ulcerative Colitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The increased expression of KAT1 and KAT3 mRNA characterized the entire cohorts of patients with UC and CD, as well as relapse-remission subsets.
|
31666808 |
2019 |
Crohn Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The increased expression of KAT1 and KAT3 mRNA characterized the entire cohorts of patients with UC and CD, as well as relapse-remission subsets.
|
31666808 |
2019 |
Hyperlipidemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that swertiamarin exerts lipid-lowering effects through kat-1 regulation and could serve as a possible therapeutic option to improve hyperlipidemia induced comorbidities.
|
30784937 |
2019 |
Inflammatory Bowel Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression of lymphocytic mRNA encoding enzymes synthesizing KYNA (KAT I-III) and serum levels of TRP and its metabolites were evaluated in 55 patients with IBD, during remission or relapse [27 patients with ulcerative colitis (UC) and 28 patients with Crohn's disease (CD)] and in 50 control individuals.
|
31666808 |
2019 |